30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

2Q14 Revenue: Biomet

(preliminary* sales for period ended 5/31/14)

FY2014 revenue:

$3,223MM, +6% (U.S. $1,970.4MM, +6%; Europe $772.0MM, +5%; International $481.0MM, +9%)

  • Hips $649.2MM, +4% (U.S. +3%)
  • Knees $995.7MM, +7% (U.S. +6%)
  • Sports/Extremities/Trauma (S.E.T.) $647.5MM, +9% (U.S. +10%)
  • Spine/Bone Healing/Microfixation $446.7MM, +9% (U.S. +7%)
  • Cement/Biologics/Other $225.2MM, +5%


FY4Q14 revenue:

$844.5MM, +7% (U.S. $498.5MM, +7%; Europe $208.9MM, +5%; International $137.1MM, +12%)

  • Hips $168.9MM, +3% (U.S. +0.4%)
  • Knees $252.4MM, +5% (U.S. +2%)
  • S.E.T. $168.7MM, +5% (U.S. +6%)
  • Spine/Bone Healing/Microfixation $124.3MM, +27% (U.S. +27%)
  • Cement/Biologics/Other $59.9MM, +7% (U.S. -0.2%)


  • Noted that 1978 annual revenue was $17,000
  • G7 multi-bearing acetabular system continued strong acceptance
  • During May, 29% of U.S. surgeons using G7 recorded as new hip customers
  • Received BSI approval to market G7 bispherical acetabular cup in Europe
  • Completed 1st G7 ceramic-on-ceramic procedure in Japan, using BIOLOX Delta ceramic head liner
  • Received Japan regulatory clearance for E1 bipolar hip
  • Notes that ~50% of hip procedures in Japan use bipolar hemiarthroplasty, a trend unique to that market
  • Continued and increasing demand for Oxford partial knee, largely due to impact of implant and instrument upgrades, DTC and warranty programs
  • >250 surgeons worldwide trained on Oxford during quarter
  • To date, >950 Vanguard XP knees implanted, commercial launch to occur in FY1Q15
  • Completed commercial launch of Vanguard SSK 360 revision in U.S. and EMEA
  • 26th consecutive quarter of double-digit extremities growth
  • Estimates ~50% of U.S. shoulder cases using Signature Patient-Specific glenoid guides during June derived from new customers
  • Planning FY1Q15 limited U.S. launch of convertible glenoid component
  • Launched DVR Volar rim plate ePAK and A.L.P.S. total foot system
  • Spine/Bone Healing cross training bringing in additional accounts; growth driven by demand for thoracolumbar hardware and biologics (Cellentra VCBM)
  • Cement sales growth supported by Japan market acceptance of Cobalt and Cobalt G

*Final results will be made available with filing of Form 10-K.